A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study
This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra
 (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who
 completed the WA19977 core study. Patients will continue to receive RoActemra/Actemra 8 mg/kg
 intravenously every 4 weeks. Anticipated time on study treatment is 104 weeks.
Inclusion Criteria:

 -  Patients who completed visit 33 (week 104) of WA19977 study and who may benefit from
 study drug treatment according to the investigator's assessment

 -  Patients have to receive the first RoActemra/Actemra infusion in this study at the
 Week 8 visit at the latest

 -  Females of child-bearing potential and males with female partners of child-bearing
 potential must agree to use effective contraception as defined by protocol

 Exclusion Criteria:

 -  Patients with, according to investigator judgment, not satisfactory benefit from
 RoActemra/Actemra therapy within WA19977

 -  Treatment with any investigational agent since the last administration of study drug
 in the core study WA19977

 -  Patient developed any other autoimmune rheumatic disease or overlap syndrome other
 than the permitted polyarticular-course Juvenile Idiopathic Arthritis (JIA) subsets:
 rheumatoid factor positive or negative JIA or extended oligoarticular JIA

 -  Patient is pregnant , lactating, or intending to become pregnant during the study and
 up to 12 weeks after the last administration of study drug

 -  Any significant concomitant disease or medical or surgical condition

 -  History of significant allergic or infusion reactions to prior biologic therapy

 -  Currently active primary or secondary immunodeficiency

 -  Any infections with contraindications to RoActemra/Actemra therapy according to
 investigator judgment

 -  Inadequate hepatic, renal or bone marrow function